Mirabella Financial Services LLP Invests $778,000 in Kenvue Inc. (NYSE:KVUE)

Mirabella Financial Services LLP bought a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,455 shares of the company’s stock, valued at approximately $778,000.

Several other institutional investors also recently bought and sold shares of the company. MML Investors Services LLC increased its holdings in shares of Kenvue by 528.3% during the fourth quarter. MML Investors Services LLC now owns 1,125,552 shares of the company’s stock valued at $24,031,000 after acquiring an additional 946,422 shares in the last quarter. MetLife Investment Management LLC grew its position in Kenvue by 1.9% during the 4th quarter. MetLife Investment Management LLC now owns 507,418 shares of the company’s stock worth $10,833,000 after purchasing an additional 9,431 shares during the last quarter. Natixis increased its stake in Kenvue by 29.3% during the 4th quarter. Natixis now owns 315,489 shares of the company’s stock valued at $6,736,000 after purchasing an additional 71,545 shares in the last quarter. Ossiam raised its holdings in shares of Kenvue by 20.5% in the fourth quarter. Ossiam now owns 4,709 shares of the company’s stock worth $101,000 after buying an additional 800 shares during the last quarter. Finally, Norinchukin Bank The lifted its stake in shares of Kenvue by 8.7% during the fourth quarter. Norinchukin Bank The now owns 85,064 shares of the company’s stock worth $1,816,000 after buying an additional 6,785 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE stock opened at $23.42 on Monday. The company has a market capitalization of $44.93 billion, a P/E ratio of 44.19, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The business’s 50 day moving average is $22.91 and its two-hundred day moving average is $22.41. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be given a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.50%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research analyst reports. Barclays reduced their target price on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, April 14th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Citigroup raised their price target on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research report on Monday, April 14th. Piper Sandler increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Finally, Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 target price for the company. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $24.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.